Skip to main content

Advertisement

SpringerLink
Log in

Effect of Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 Alpha Variants on Spontaneous Clearance and Fibrosis Progression during Hepatitis C Virus Infection in Moroccan Patients

  • RESEARCH ARTICLE
  • Published:
Virologica Sinica

Abstract

Hepatitis C virus (HCV) is still one of the main causes of liver disease worldwide. Metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), induced by HCV have been shown to accelerate the progression of fibrosis to cirrhosis and to increase the risk of hepatocellular carcinoma. An optimal peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) activity is crucial to prevent NAFLD installation. The present study aims to investigate the associations between two common PPARGC1A polymorphisms (rs8192678 and rs12640088) and the outcomes of HCV infection in a North African context. A series of 592 consecutive Moroccan subjects, including 292 patients with chronic hepatitis C (CHC), 100 resolvers and 200 healthy controls were genotyped using a TaqMan allelic discrimination assay. PPARGC1A variations at rs8192678 and rs12640088 were not associated with spontaneous clearance of HCV infection (adjusted ORs = 0.76 and 0.79 respectively, P > 0.05, for both). Furthermore, multivariable logistic regression analysis showed that both SNPs were not associated with fibrosis progression (OR = 0.71; 95% CI 0.20–2.49; P = 0.739; OR = 1.28; 95% CI 0.25–6.54; P = 0.512, respectively). We conclude that, in the genetic context of South Mediterranean patients, rs8192678 and rs12640088 polymorphisms of PPARGC1A are neither associated with spontaneous clearance nor with disease progression in individuals infected with HCV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, O’Rahilly S, Wareham NJ (2006) Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 49:501–505

    CAS  PubMed  Google Scholar 

  • Burgueno AL, Cabrerizo R, Gonzales Mansilla N, Sookoian S, Pirola CJ (2013) Maternal high-fat intake during pregnancy programs metabolic-syndrome-related phenotypes through liver mitochondrial DNA copy number and transcriptional activity of liver ppargc1a. J Nutr Biochem 24:6–13

    CAS  PubMed  Google Scholar 

  • Chen Y, Mu P, He S, Tang X, Guo X, Li H, Xu H, Woo SL, Qian X, Zeng L, Wu C (2013) Gly482ser mutation impairs the effects of peroxisome proliferator-activated receptor gamma coactivator-1alpha on decreasing fat deposition and stimulating phosphoenolpyruvate carboxykinase expression in hepatocytes. Nutr Res 33:332–339

    CAS  PubMed  Google Scholar 

  • Cheng Y, Dharancy S, Malapel M, Desreumaux P (2005) Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1a. World J Gastroenterol 11:7591–7596

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cheng CF, Ku HC, Lin H (2018) PGC-1alpha as a pivotal factor in lipid and metabolic regulation. Int J Mol Sci 19:3447

    PubMed Central  Google Scholar 

  • Choi J, Ou JH (2006) Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis c virus. Am J Physiol Gastrointest Liver Physiol 290:G847–G851

    CAS  PubMed  Google Scholar 

  • Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, Gambiez L, Mathurin P, Paris JC, Schoonjans K, Calmus Y, Pol S, Auwerx J, Desreumaux P (2005) Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 128:334–342

    CAS  PubMed  Google Scholar 

  • Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O (2001) Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type ii diabetes mellitus. Diabetologia 44:2220–2226

    CAS  PubMed  Google Scholar 

  • Estall JL, Kahn M, Cooper MP, Fisher FM, Wu MK, Laznik D, Qu L, Cohen DE, Shulman GI, Spiegelman BM (2009) Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes 58:1499–1508

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ezzikouri S, Elfihry R, Chihab H, Elmessaoudi-Idrissi M, Zaidane I, Jadid FZ, Karami A, Tahiri M, Elhabazi A, Kabine M, Chair M, Pineau P, Benjelloun S (2018) Effect of MBOAT7 variant on hepatitis B and C infections in moroccan patients. Sci Rep 8:12247

    PubMed  PubMed Central  Google Scholar 

  • Finck BN, Kelly DP (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116:615–622

    CAS  PubMed  PubMed Central  Google Scholar 

  • Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944–948

    CAS  PubMed  Google Scholar 

  • Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J (2003) Insulin resistance is associated with chronic hepatitis c virus infection and fibrosis progression [corrected]. Gastroenterology 125:1695–1704

    CAS  PubMed  Google Scholar 

  • Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM (2010) Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 8:1017–1029

    PubMed  Google Scholar 

  • Knobler H, Schattner A (2005) TNF-α, chronic hepatitis c and diabetes: a novel triad. QJM 98:1–6

    CAS  PubMed  Google Scholar 

  • Kunej T, Globocnik Petrovic M, Dovc P, Peterlin B, Petrovic D (2004) A Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene is associated with type 2 diabetes in caucasians. Folia Biol (Praha) 50:157–158

    CAS  Google Scholar 

  • Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345:41–52

    CAS  PubMed  Google Scholar 

  • Lazo M, Nwankwo C, Daya NR, Thomas DL, Mehta SH, Juraschek S, Willis K, Selvin E (2017) Confluence of epidemics of hepatitis C, diabetes, obesity, and chronic kidney disease in the united states population. Clin Gastroenterol Hepatol 15(1957–1964):e1957

    Google Scholar 

  • Li X, Monks B, Ge Q, Birnbaum MJ (2007) Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447:1012–1016

    CAS  PubMed  Google Scholar 

  • Liu R, Zhang H, Zhang Y, Li S, Wang X, Wang X, Wang C, Liu B, Zen K, Zhang CY, Zhang C, Ba Y (2017) Peroxisome proliferator-activated receptor gamma coactivator-1 alpha acts as a tumor suppressor in hepatocellular carcinoma. Tumour Biol 39:1010428317695031

    PubMed  Google Scholar 

  • Maeno T, Okumura A, Ishikawa T, Kato K, Sakakibara F, Sato K, Ayada M, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S (2003) Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 18:1358–1363

    CAS  PubMed  Google Scholar 

  • Mirzaei K, Hossein-nezhad A, Emamgholipour S, Ansar H, Khosrofar M, Tootee A, Alatab S (2012) An exonic peroxisome proliferator-activated receptor-gamma coactivator-1alpha variation may mediate the resting energy expenditure through a potential regulatory role on important gene expression in this pathway. J Nutrigenet Nutrigenomics 5:59–71

    CAS  PubMed  Google Scholar 

  • Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP (2005) Viral and host factors in early hepatitis C virus infection. Hepatology 42:86–92

    CAS  PubMed  Google Scholar 

  • Musaiger AO (2011) Overweight and obesity in eastern mediterranean region: prevalence and possible causes. J Obes 2011:407237

    PubMed  PubMed Central  Google Scholar 

  • Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D (1998) Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28:1687–1695

    CAS  PubMed  Google Scholar 

  • Parvaiz F, Manzoor S, Iqbal J, McRae S, Javed F, Ahmed QL, Waris G (2014) Hepatitis C virus nonstructural protein 5a favors upregulation of gluconeogenic and lipogenic gene expression leading towards insulin resistance: a metabolic syndrome. Arch Virol 159:1017–1025

    CAS  PubMed  Google Scholar 

  • Qadri I, Choudhury M, Rahman SM, Knotts TA, Janssen RC, Schaack J, Iwahashi M, Puljak L, Simon FR, Kilic G, Fitz JG, Friedman JE (2012) Increased phosphoenolpyruvate carboxykinase gene expression and steatosis during hepatitis C virus subgenome replication: role of nonstructural component 5a and CCAAT/enhancer-binding protein beta. J Biol Chem 287:37340–37351

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Goni L, Cuervo M, Martinez JA (2018) Association of the Gly482Ser PPARGC1A gene variant with different cholesterol outcomes in response to two energy-restricted diets in subjects with excessive weight. Nutrition 47:83–89

    CAS  PubMed  Google Scholar 

  • Saremi L, Lotfipanah S, Mohammadi M, Hosseinzadeh H, Hosseini-Khah Z, Johari B, Saltanatpour Z (2019) Association between ppargc1a single nucleotide polymorphisms and increased risk of nonalcoholic fatty liver disease among iranian patients with type 2 diabetes mellitus. Turk J Med Sci 49:1089–1094

    CAS  PubMed  PubMed Central  Google Scholar 

  • Shlomai A, Rechtman MM, Burdelova EO, Zilberberg A, Hoffman S, Solar I, Fishman S, Halpern Z, Sklan EH (2012) The metabolic regulator PGC-1alpha links hepatitis C virus infection to hepatic insulin resistance. J Hepatol 57:867–873

    CAS  PubMed  Google Scholar 

  • Soyal S, Krempler F, Oberkofler H, Patsch W (2006) Pgc-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia 49:1477–1488

    CAS  PubMed  Google Scholar 

  • Tai CM, Huang CK, Tu HP, Hwang JC, Yeh ML, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML (2016) Interactions of a PPARGC1A variant and a PNPLA3 variant affect nonalcoholic steatohepatitis in severely obese taiwanese patients. Medicine (Baltimore) 95:e3120

    CAS  Google Scholar 

  • Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T (2008) Pparalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118:683–694

    PubMed  PubMed Central  Google Scholar 

  • Tazi MA, Abir-Khalil S, Chaouki N, Cherqaoui S, Lahmouz F, Srairi JE, Mahjour J (2003) Prevalence of the main cardiovascular risk factors in Morocco: results of a national survey, 2000. J Hypertens 21:897–903

    CAS  PubMed  Google Scholar 

  • Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450–456

    CAS  PubMed  Google Scholar 

  • Villegas R, Williams SM, Gao YT, Long J, Shi J, Cai H, Li H, Chen CC, Tai ES, Consortium A-TD, Hu F, Cai Q, Zheng W, Shu XO (2014) Genetic variation in the peroxisome proliferator-activated receptor (PPAR) and peroxisome proliferator-activated receptor gamma co-activator 1 (PGC1) gene families and type 2 diabetes. Ann Hum Genet 78:23–32

    CAS  PubMed  PubMed Central  Google Scholar 

  • Vohl MC, Houde A, Lebel S, Hould FS, Marceau P (2005) Effects of the peroxisome proliferator-activated receptor-gamma co-activator-1 Gly482Ser variant on features of the metabolic syndrome. Mol Genet Metab 86:300–306

    CAS  PubMed  Google Scholar 

  • White DL, Ratziu V, El-Serag HB (2008) Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 49:831–844

    PubMed  PubMed Central  Google Scholar 

  • WHO (2017) Guidelines on hepatitis b and c testing, p 204, Licence: CC BY-NC-SA 3.0 IGO, February 2017 edn

  • Yao W, Cai H, Li X, Li T, Hu L, Peng T (2014) Endoplasmic reticulum stress links hepatitis C virus RNA replication to wild-type PGC-1alpha/liver-specific PGC-1alpha upregulation. J Virol 88:8361–8374

    PubMed  PubMed Central  Google Scholar 

  • Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, Iida H, Kato S, Hosono K, Fujita K, Yoneda K, Takahashi H, Kirikoshi H, Kobayashi N, Inamori M, Abe Y, Kubota K, Saito S, Maeyama S, Wada K, Nakajima A (2008) Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 8:27

    PubMed  PubMed Central  Google Scholar 

  • Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Chen Y, Liu L (2018) Relationship of PPARG, PPARGC1A, and PPARGC1B polymorphisms with susceptibility to hepatocellular carcinoma in an Eastern Chinese Han population. Onco Targets Ther 11:4651–4660

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge all patients for their participation in this study.

Author information

Authors and Affiliations

  1. Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 20360, Casablanca, Morocco

    Raouia ElFihry, Mohcine Elmessaoudi-Idrissi, Fatima-Zahra Jadid, Imane Zaidane, Hajar Chihab, Sayeh Ezzikouri & Soumaya Benjelloun

  2. Laboratoire Santé et Environnement, département de Biologie, Faculté des Sciences Ain Chock, University Hassan II of Casablanca, 20360, Casablanca, Morocco

    Raouia ElFihry & Mostafa Kabine

  3. Service d’Hépato-Gastro-Entérologie, CHU Ibn Rochd, 20360, Casablanca, Morocco

    Mohamed Tahiri & Wafaa Badre

  4. Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052, CNRS 5286, Lyon Cedex 03, France

    Isabelle Chemin

  5. Unité “Organisation Nucléaire et Oncogenèse”, INSERM U993, Institut Pasteur, 75015, Paris, France

    Agnes Marchio & Pascal Pineau

Authors
  1. Raouia ElFihry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohcine Elmessaoudi-Idrissi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatima-Zahra Jadid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Imane Zaidane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hajar Chihab
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohamed Tahiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mostafa Kabine
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wafaa Badre
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Isabelle Chemin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Agnes Marchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pascal Pineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sayeh Ezzikouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Soumaya Benjelloun
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SB, SE, RE conceived, designed the experiments and wrote the paper; SB, SE, MK and PP contributed to the drafting and revision of the article; IZ, FZJ and HC helped in the collection of samples; WB and MT contributed to the clinical data; MEI helped in the statistical analysis; IC and AM helped in the interpretation of data; SB contributed to the final approval of the version to be submitted. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Sayeh Ezzikouri or Soumaya Benjelloun.

Ethics declarations

Conflict of interest

Authors declare that they have no conflict of interest.

Animal and Human Rights Statement

The study was approved by the Ethics Committee of the Faculty of Medicine of Casablanca in accordance with the ethical guidelines of the Declaration of Helsinki. For study participation, written informed consent for genetic testing was obtained from all subjects.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ElFihry, R., Elmessaoudi-Idrissi, M., Jadid, FZ. et al. Effect of Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 Alpha Variants on Spontaneous Clearance and Fibrosis Progression during Hepatitis C Virus Infection in Moroccan Patients. Virol. Sin. 35, 566–574 (2020). https://doi.org/10.1007/s12250-020-00220-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12250-020-00220-7

Keywords

Search

Navigation